It made selective toxicity practical
Ehrlich hoped that chemical compounds could damage pathogens more than patients. Salvarsan did not fulfil that ideal perfectly, but it made selective action a concrete research goal.
Timeline Entry
Salvarsan Introduced, 1910
In 1910, arsphenamine, marketed as Salvarsan, entered medical use as a treatment for syphilis. Developed in Paul Ehrlich's laboratory with Sahachiro Hata and other collaborators, it became one of the best-known early examples of systematic chemotherapy.
Salvarsan matters because it showed that laboratory screening could produce a drug aimed at a specific infectious organism, while also revealing the toxicity, administration, regulation, and access problems of early modern therapeutics.
Historical Significance
A drug-screening program became a therapeutic event
It transformed syphilis treatment
Before penicillin, syphilis treatment relied on difficult and often toxic regimens. Salvarsan offered a more targeted option, though it required careful handling and clinical supervision.
It linked laboratories, industry, and clinics
The drug's history depended on chemical manufacture, distribution, clinical testing, physician technique, and public demand. It showed that modern drugs were institutional products, not only laboratory discoveries.
Reading Path
Where this entry fits
Read this entry with Paul Ehrlich, Penicillin, 1928, History of Antibiotics and Penicillin, and History of Pharmacy and Apothecaries.